787 logo

Selvita DB:787 Stock Report

Last Price

€14.74

Market Cap

€264.5m

7D

-1.9%

1Y

-7.1%

Updated

14 Jun, 2024

Data

Company Financials +

787 Stock Overview

Operates as a contract research organization worldwide.

787 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance5/6
Financial Health3/6
Dividends0/6

Selvita S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Selvita
Historical stock prices
Current Share Pricezł14.74
52 Week Highzł17.04
52 Week Lowzł12.40
Beta0.055
1 Month Change-7.41%
3 Month Change7.12%
1 Year Change-7.06%
3 Year Change-9.01%
5 Year Changen/a
Change since IPO19.35%

Recent News & Updates

Recent updates

Shareholder Returns

787DE Life SciencesDE Market
7D-1.9%-3.1%-2.3%
1Y-7.1%-19.6%1.0%

Return vs Industry: 787 exceeded the German Life Sciences industry which returned -19.6% over the past year.

Return vs Market: 787 underperformed the German Market which returned 1% over the past year.

Price Volatility

Is 787's price volatile compared to industry and market?
787 volatility
787 Average Weekly Movement4.6%
Life Sciences Industry Average Movement5.5%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.4%
10% least volatile stocks in DE Market2.6%

Stable Share Price: 787 has not had significant price volatility in the past 3 months.

Volatility Over Time: 787's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007387Boguslaw Sieczkowskiselvita.com

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis.

Selvita S.A. Fundamentals Summary

How do Selvita's earnings and revenue compare to its market cap?
787 fundamental statistics
Market cap€264.45m
Earnings (TTM)€14.93m
Revenue (TTM)€77.13m

17.7x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
787 income statement (TTM)
Revenuezł337.26m
Cost of Revenuezł68.59m
Gross Profitzł268.66m
Other Expenseszł203.37m
Earningszł65.30m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Sep 25, 2024

Earnings per share (EPS)3.56
Gross Margin79.66%
Net Profit Margin19.36%
Debt/Equity Ratio36.1%

How did 787 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.